The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.

As IL-6 inhibition comes into practice for PMR, research advances on other therapeutic mechanisms of action, from IL-17 to ...

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

This time, her baby did test positive for SMA type 1, a severe neurodegenerative genetic condition that typically results in ...

A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...

Gepotidacin and nitrofurantoin demonstrate similar efficacy in reducing symptom severity and restoring daily function in women with uncomplicated UTI.

The drug leucovorin was touted by the Trump administration in September as a potential treatment for thousands of children with autism. Now, some parents and guardians of children with autism say they ...

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant ...

The foundation helps fund youth sports programs, cancer organizations and mental health nonprofits, delivering the message "We care." ...

March 11 (Reuters) - Regenxbio said on Wednesday that interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued ...

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...